Evolus plunges after Q2 miss, guidance cut; Needham downgrades
Source: SeekingAlpha
2025-08-06 15:31:08 ET
More on Evolus
- Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript
- Evolus, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings
- Evolus outlines $700M 2028 revenue target and cost realignment amid market softness
- Evolus GAAP EPS of -$0.27 misses by $0.07, revenue of $69.4M misses by $12.64M
Read the full article on Seeking Alpha
For further details see:
Evolus plunges after Q2 miss, guidance cut; Needham downgrades
Evolus Inc.
NASDAQ: EOLS
EOLS Trading
-2.42% G/L:
$5.24 Last:
197,327 Volume:
$5.30 Open:
EOLS Latest News
EOLS Stock Data
$288,448,039
43,258,131
1.1%
49
N/A
Pharmaceuticals
Healthcare
US
Newport Beach
